GPR119 - G protein-coupled receptor 119 Gene
Also Known as GPCR2
Species: Homo sapiens
Gene Type: protein coding
Gene ID: 139760
About GPR119
Cytogenetic location: Xq26.1
Genomic coordinates (GRCh38): X:130,379,449-130,385,674 (from NCBI)
This gene has 2 transcripts (splice variants), 176 orthologues and 18 paralogues.
Summary
This gene encodes a member of the rhodopsin subfamily of G-protein-coupled receptors that is expressed in the pancreas and gastrointestinal tract. The encoded protein is activated by lipid amides including lysophosphatidylcholine and oleoylethanolamide and may be involved in glucose homeostasis. This protein is a potential drug target in the treatment of type 2 diabetes.[provided by RefSeq, Jan 2010]
GPR119 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_178471.3 | NP_848566.1 | glucose-dependent insulinotropic receptor |
| Molecular Function GO Annotation | Evidence | References | Source |
|---|---|---|---|
| enables protein binding |
IPI
IPI: Inferred from physical interaction
|
32296183 | GOA |
| Cellular Component GO Annotation | Evidence | References | Source |
|---|---|---|---|
| part of receptor complex |
IDA
IDA: Inferred from direct assay
|
23382219 | GOA |
EXP: Inferred from Experiment
IDA: Inferred from direct assay
IPI: Inferred from physical interaction
IMP: Inferred from mutant phenotype
IGI: Inferred from genetic interaction
IEP: Inferred from expression pattern
GPR119 Protein Structure
7tm_1
7tm_1: 7 transmembrane receptor (rhodopsin family) (22 - 279)
- 0
- 100
- 200
- 300
- 335 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
glucose-dependent insulinotropic receptor |
|
Related Diseases
| Diseases | Alias | |
|---|---|---|
| Diabetes Mellitus |
|
Related Agents
- Clinical Phase
- Pre-clinical Phase
Clinical Phase
Bioactive Molecules
(5)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-15291 | MBX-2982 | Agonist | 99.68% | Phase 2 |
| HY-12066 | GSK1292263 | Agonist | 99.71% | Phase 2 |
| HY-109032 | Firuglipel | Agonist | 99.91% | Phase 2 |
| HY-15565 | APD668 | Agonist | 99.73% | Phase 1 |
| HY-15566 | APD597 | Agonist | 99.97% | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(28)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-W011121 | 2-Oleoylglycerol | Agonist | 99.9% | Unkown |
| HY-15564 | AR 231453 | Agonist | 99.58% | Unkown |
| HY-171454 | DA-1241 | Agonist | 99.18% | Unkown |
| HY-107535 | AS1269574 | Agonist | 99.84% | Unkown |
| HY-16673 | PSN632408 | Agonist | 99.30% | Unkown |
| HY-12375 | BMS-903452 | Agonist | 99.70% | Unkown |
| HY-108258 | PSN 375963 | Agonist | 99.95% | Unkown |
| HY-120637 | BMS-986034 | Agonist | / | Unkown |
| HY-W701772 | 2-Oleoylglycerol-d5 | / | Unkown | |
| HY-182454 | GPR119 agonist 4 | Agonist | / | Unkown |
| HY-155553 | GPR119 agonist 2 | Agonist | / | Unkown |
| HY-146468 | DPP-4/GPR119 modulator 1 | Agonist | / | Unkown |
| HY-126807 | AS1907417 | Agonist | / | Unkown |
| HY-113653 | GSK2041706A | Agonist | / | Unkown |
| HY-115643 | AZ13581837 | Agonist | / | Unkown |
| HY-172120 | GPR119 agonist 3 | Agonist | / | Unkown |
| HY-178780 | MKP10241 | Agonist | 98.06% | Unkown |
| HY-108258A | PSN 375963 hydrochloride | Agonist | / | Unkown |
| HY-182580 | HBK001 | Agonist | / | Unkown |
| HY-146469 | DPP-4/GPR119 modulator 2 | Agonist | / | Unkown |
| HY-124978 | MK-8282 | Agonist | / | Unkown |
| HY-125646 | YH18968 | Activator | / | Unkown |
| HY-18354 | GSK1104252A | Activator | / | Unkown |
| HY-12066A | GSK-1292263 hydrochloride | Agonist | / | Unkown |
| HY-175422 | K-833 | Agonist | / | Unkown |
| HY-113243 | 1-Oleoyl lysophosphatidylcholine | Activator | / | Unkown |
| HY-117446A | AS-1669058 free base | Agonist | / | Unkown |
| HY-117446 | AS-1669058 | Agonist | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service